Compare Eli Lilly And Co (LLY) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B). The key difference: Eli Lilly And Co is far larger — about 9.1× iShares 0 3 Month Treasury Bond ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| LLY | SGOV | |
|---|---|---|
Market Cap | $1.04T | $114.40B |
Volume | 3,064,878 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $1.28K | $100.72 |
52-Week Low | $799.57 | $100.28 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.47 with minimal daily movement, reflecting its ultra-short-term Treasury focus. The technical picture shows bearish momentum with moving averages signaling caution, though oversold RSI levels suggest potential stabilization. Recent institutional activity includes Envestnet Asset Management reducing its position by 13.2% in Q2 2026 (SEC filing, September 25, 2026).
As a Treasury ETF, SGOV offers low volatility and regular dividend distributions, with recent payouts around $0.30-$0.31. However, rising bond yields and Federal Reserve policy uncertainty create headwinds. The fund provides capital preservation but limited growth potential in a rising rate environment, making it suitable for defensive positioning rather than aggressive growth strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
